5.22.25
NEWS & EVENTS
What’s “c/λ” at Accent?
News
4.28.25
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
4.15.25
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559
3.25.25
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
12.11.24
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition
10.24.24
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
4.8.24
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting
3.21.24